Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by HB Wealth Management LLC

HB Wealth Management LLC cut its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 15.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,171 shares of the medical equipment provider’s stock after selling 2,857 shares during the quarter. HB Wealth Management LLC’s holdings in Zimmer Biomet were worth $1,475,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ZBH. Brighton Jones LLC acquired a new position in Zimmer Biomet in the fourth quarter valued at approximately $204,000. Wealth Enhancement Advisory Services LLC lifted its holdings in Zimmer Biomet by 25.1% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 18,353 shares of the medical equipment provider’s stock valued at $1,939,000 after acquiring an additional 3,681 shares during the period. NBC Securities Inc. lifted its holdings in Zimmer Biomet by 176,700.0% in the first quarter. NBC Securities Inc. now owns 1,768 shares of the medical equipment provider’s stock valued at $200,000 after acquiring an additional 1,767 shares during the period. Gilman Hill Asset Management LLC lifted its holdings in Zimmer Biomet by 3.9% in the first quarter. Gilman Hill Asset Management LLC now owns 29,120 shares of the medical equipment provider’s stock valued at $3,296,000 after acquiring an additional 1,081 shares during the period. Finally, Lmcg Investments LLC lifted its holdings in Zimmer Biomet by 9.5% in the first quarter. Lmcg Investments LLC now owns 61,260 shares of the medical equipment provider’s stock valued at $6,933,000 after acquiring an additional 5,311 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares of the company’s stock, valued at approximately $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Trading Up 0.3%

Shares of ZBH stock opened at $99.14 on Friday. The stock has a 50 day simple moving average of $100.80 and a 200-day simple moving average of $98.89. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The company has a market cap of $19.64 billion, a price-to-earnings ratio of 24.12, a PEG ratio of 2.28 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. During the same period in the prior year, the company earned $2.01 EPS. The firm’s revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ZBH shares. Raymond James Financial boosted their price target on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Redburn Partners set a $130.00 target price on Zimmer Biomet in a research note on Thursday, September 18th. UBS Group upped their target price on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research note on Friday, August 8th. Rothschild & Co Redburn began coverage on Zimmer Biomet in a research note on Thursday, September 18th. They set a “buy” rating and a $130.00 target price for the company. Finally, Stifel Nicolaus upped their target price on Zimmer Biomet from $115.00 to $118.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Moderate Buy” and an average price target of $112.44.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.